erthang: I want to see some more proof of concept on the diagnostics side before I start thinking about that stuff. I'm a bit concerned that the company refuses to pay for a larger, independant study of RECAF's diagnostic applications. I've spoken to some people that say it wouldn't be more than a few hundred dollars per sample through any of the major third-party testing labs. In other words, BOCX could get certified data from an established, independant party for 500 samples or so for only $100 - $200k. Next time you speak to Moro I beg you to ask him why he refuses to pursue a semi-conclusive data set like that, which would clearly open the doors to more investors and pharma partnerships.
DISCLAIMER: NEVER ASSUME INFO ON MESSAGE BOARDS TO BE ACCURATE. ALWAYS DO YOUR OWN DUE DILIGENCE. DON'T BUY STOCK BASED ON THIS POST OR ANY OTHER POST. I OWN A LONG POSITION IN THIS STOCK AND THEREFORE I AM BIASED.